---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024496"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-22T00:00:55.119006+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics Q3 net loss $30.7M; cash runway extended to mid-2024

## Summary
- Cash and investments $149.5M as of Sept 30; funds expected to support operations to mid-2024.
- R&D expenses $23.8M, G&A $7.5M; net loss $30.7M ($0.74 per share).
- Dosing started in Phase 1 trial for TN-301 (HDAC6 inhibitor for HFpEF); data expected in 2023.
- Plans to submit IND for TN-201 (MYBPC3 gene therapy for HCM) by year-end 2022; IND for TN-401 in 2023.
- USPTO granted patent for TN-201 covering AAV therapy with MYBPC3; patent for TN-301 HDAC6 inhibitor allowed.

## SEC filing metadata
- accession: 0000950170-22-024496
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017022024496/0000950170-22-024496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017022024496/tnya-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024496
- JSON: https://secwatch.observer/filing/0000950170-22-024496.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024496.txt

## Key facts
- Earnings Releases
  Tenaya Therapeutics, Inc. reported third quarter ended September 30, 2022 results: net income Net loss for the second quarter ended September 30, 2022, was $30.7 million, or $0.74 per share., EPS $0.74 per share.
  - Period: third quarter ended September 30, 2022
  - Net income: Net loss for the second quarter ended September 30, 2022, was $30.7 million, or $0.74 per share.
  - EPS: $0.74 per share
  - Result: reported results
  source text: Tenaya Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017022024496/0000950170-22-024496-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.